Translating biomarker discoveries into novel diagnostics and therapeutics for Chronic Obstructive Pulmonary Disease (COPD). The biomarkers have been identified.
Lenimen's intellectual property is set to change the standard of care as is relates to risk stratification and pharmacological therapies in COPD. Recent legislative changes have exposed U.S. hospitals to a billion dollars in direct penalties and over $1.3 billion in uncompensated care due to hospital readmissions. Lenimen’s near term market opportunity is estimated at $250M annually thru the reduction in hospital readmission rates for COPD.